Genmab A/S (GMAB) Competitors

Takeda Pharmaceutical (NYSE:TAK) and Genmab A/S (NASDAQ:GMAB) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership.

Does the media prefer TAK or GMAB?

In the previous week, Genmab A/S had 5 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 10 mentions for Genmab A/S and 5 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 1.55 beat Genmab A/S's score of 1.10 indicating that Takeda Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Genmab A/S	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk and volatility, TAK or GMAB?

Takeda Pharmaceutical has a beta of 0.23, indicating that its stock price is 77% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500.

Which has higher valuation & earnings, TAK or GMAB?

Genmab A/S has lower revenue, but higher earnings than Takeda Pharmaceutical. Genmab A/S is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$4.58T	0.01	$712.33M	$0.22	66.68
Genmab A/S	$3.12B	4.40	$1.14B	$1.76	12.16

Is TAK or GMAB more profitable?

Genmab A/S has a net margin of 35.11% compared to Takeda Pharmaceutical's net margin of 2.36%. Genmab A/S's return on equity of 18.08% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	2.36%	10.64%	5.14%
Genmab A/S	35.11%	18.08%	14.52%

Do analysts prefer TAK or GMAB?

Genmab A/S has a consensus price target of $37.80, indicating a potential upside of 76.64%. Given Genmab A/S's higher probable upside, analysts clearly believe Genmab A/S is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Genmab A/S	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.67

Do institutionals & insiders hold more shares of TAK or GMAB?

9.2% of Takeda Pharmaceutical shares are owned by institutional investors. Comparatively, 7.1% of Genmab A/S shares are owned by institutional investors. 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Comparatively, 1.5% of Genmab A/S shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Genmab A/S beats Takeda Pharmaceutical on 12 of the 17 factors compared between the two stocks.